Clinical Trials Logo

Clinical Trial Summary

Tourniquet inflation during total knee arthroplasty (TKA) is commonly used to reduce bleeding in the surgical field; thereby facilitating exposure and cementation. However, reducing circulation to the leg may also reduce antibiotic distribution to the peri-incisional tissues. Once inflated, further parenteral addition of antibiotics is not likely to achieve peak concentration. Some studies propose techniques of regional prophylaxis with a tourniquet to achieve higher cefazolin tissue concentrations. To our knowledge, the effect of tourniquet application on antibiotic tissue concentrations during total knee arthroplasty has not been explored. Furthermore, the effect of time from dose to incision, participants weight, and length of surgery on local tissue concentrations of Ancef are poorly understood. Considering that infections remain the leading source of early reoperation and revision surgery, insight and optimization of local tissue antibiotics is of paramount interest.


Clinical Trial Description

In Canada, over 130 000 cases of primary joint arthroplasty are performed annually, and this number is increasing steadily with the aging population. Projections from the United States estimate that, by 2030, more than 3.5 million primary joint arthroplasties will be performed annually. Although rare, with reported rates of 0.5-2% within 2 years, periprosthetic joint infection (PJI) is a devastating complication with serious morbidity. Effective use of antibiotic prophylaxis remains an important measure to prevent progression of an intraoperative contamination of the surgical site to an overt clinical infection. It creates a hostile environment in blood and tissue inhibiting pathogens that could contaminate the wound throughout the procedure. In order to be effective, the concentration of antibiotic must exceed the minimum inhibitory concentration (MIC) of the organism between skin incision and wound closure. S. aureus and Coagulase-negative staphylocci (CoNS), including S.epidermidis, cause close to half of deep infections and reported MIC ranges from 0.5 to 8 ug/ml in bone. Achieving fourfold MIC in tissue is recommended for halting the pathogen Cefazolin, efficient against most common pathogens in orthopaedics, has a good tissue penetration, minimal toxicity, low cost, and therefore is the antibiotic of choice in arthroplasty procedures. Pharmacokinetics studies have showed that Cefazolin achieves peak bone concentrations 40 minutes after parenteral application and based on systemic dosage methods, guidelines recommend that the antibiotic should be infused within 60 minutes before surgical incision. Compared to conventional systemic dosing, modern techniques using liquid chromatography and mass spectrometry can adequately measure antibiotic concentration in tissue like fat and bone. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05604157
Study type Interventional
Source McGill University Health Centre/Research Institute of the McGill University Health Centre
Contact Adam Hart, MD
Phone 514-934-1934
Email adam.hart@mgcill.ca
Status Recruiting
Phase N/A
Start date September 16, 2021
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05902221 - Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections Phase 3
Not yet recruiting NCT06451224 - Egyptian Arthroplasty Surgeons' Antibiotics Usage Awareness
Enrolling by invitation NCT04297592 - Antibiotic Prophylaxis in High-Risk Arthroplasty Patients Phase 4
Recruiting NCT04620395 - Percutaneous Punch Biopsy for Diagnosis of Septic and Aseptic Prosthetic Joint Failure N/A